Neuregulin-1 exerts antifibrotic effects across multiple tissues (heart, skin, lung) via anti-inflammatory macrophage activation through the ErbB4 pathway.
May guide macrophage ErbB4-targeted antifibrotic research across tissues; leaves open human translation from animal data.
Our study contributes to the understanding of the antifibrotic effect of neuregulin-1 during myocardial remodeling. Here, we show that the antifibrotic effect of neuregulin-1 is at least partially mediated through anti-inflammatory activity, linked to receptor tyrosine-protein kinase erbB-4 activation in macrophages. Furthermore, we show that this effect is also present outside the heart.
No takes yet. Share an insight, caveat, or question.
Vermeulen et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: